Results 131 to 140 of about 1,866 (169)
Bimekizumab Versus Adalimumab in Plaque Psoriasis
New England Journal of Medicine, 2021 BACKGROUND: Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with the tumor necrosis factor inhibitor adalimumab in patients with moderate-to ...
Kristian Reich, Kim A. Papp
exaly +4 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Acne Conglobata and Bimekizumab.
JAMA DermatologyThis case report describes 2 patients who received off-label bimekizumab for treatment-resistent acne conglobata.
Matiar Madanchi +3 more
semanticscholar +3 more sources
Bimekizumab Treatment in Patients With Moderate to Severe Plaque Psoriasis: A Drug Safety Evaluation
Expert Opinion on Drug Safety, 2023 Introduction: Biological treatments deeply changed the management of moderate to severe forms of psoriasis. Among available biological therapies, interleukin (IL)-17 inhibitors, secukinumab, ixekizumab, brodalumab, and bimekizumab, represent one of the ...
Alessia Villani +2 more
exaly +2 more sources
Drugs of Today, 2022
Psoriasis is a chronic, immune-mediated, inflammatory skin disease, affecting 1% to 3% of the population in Western countries. Due to advances in the understanding of psoriasis pathogenesis, in particular, the role of the interleukin-23 (IL-23)/T-helper 17 (Th17) immune axis, highly effective, targeted biologic therapies have been developed, shifting ...
Maria Alexandra, Rodrigues +2 more
openaire +2 more sources
Psoriasis is a chronic, immune-mediated, inflammatory skin disease, affecting 1% to 3% of the population in Western countries. Due to advances in the understanding of psoriasis pathogenesis, in particular, the role of the interleukin-23 (IL-23)/T-helper 17 (Th17) immune axis, highly effective, targeted biologic therapies have been developed, shifting ...
Maria Alexandra, Rodrigues +2 more
openaire +2 more sources
Lancet, TheBACKGROUND Patients with hidradenitis suppurativa have substantial unmet clinical needs and scarce therapeutic options. We aimed to assess the efficacy and safety of bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F ...
Luke Peterson +2 more
exaly +2 more sources
Bimekizumab for the Treatment of Psoriasis
Drugs, 2021Psoriasis is a chronic, systemic, immune-mediated disease, with prominent skin and joint manifestations, associated with several comorbidities. In the past few decades, advances in the knowledge of psoriasis pathogenesis have driven the development of highly effective targeted biologic therapies, transforming the treatment landscape of psoriasis ...
Egídio Freitas +2 more
openaire +2 more sources
Journal of DermatologyBimekizumab, which suppresses both interleukin (IL)‐17A and IL‐17F, has recently been approved as a biologic for psoriasis. We aimed to evaluate the real‐world effectiveness and safety of bimekizumab for psoriasis and to identify predictive factors for ...
Hidehisa Saeki +2 more
exaly +2 more sources
Canadian Journal of Health Technologies, 2022
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +2 more sources
CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments ...
openaire +2 more sources
Bimekizumab for The Treatment of Psoriasis
ImmunotherapyPsoriasis is a chronic inflammatory skin condition characterized by Th17 T cell-mediated inflammation. An emerging treatment option for psoriasis is bimekizumab, a humanized monoclonal antibody targeting cytokines IL-17A and IL-17F. Phase I trials evaluating bimekizumab reported strong safety, tolerability, and clinical efficacy with most common ...
Molly Thapar +2 more
openaire +2 more sources